All In Biotech

Drug Trial Radar · NCT05775159

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

294

Planned (sponsor's estimate)

Start

Apr 24, 2023

Primary completion

Oct 27, 2026

Study completion Oct 28, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Conditions

  • Hepatocellular Carcinoma
  • Biliary Tract Cancer

Interventions

  • VolrustomigDrug

    CTLA-4/Anti-PD-1 Bispecific Antibody

  • BevacizumabDrug

    15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • LenvatinibDrug

    Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • RilvegostomigDrug

    anti- PD-1 and TIGIT bispecific antibody

  • GemcitabineDrug

    1000 mg/m2, IV infusion

  • CisplatinDrug

    25 mg/m2, IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Through study completion, an average of 2 years
  2. The number of participants with adverse events/serious adverse eventsTime frame: Through study completion, an average of 2 years
  3. Progression free survival (PFS)Time frame: Through study completion, an average of 2 years

Locations

46 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Kansas City, Kansas

  • Research Site

    New York, New York

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Nanning, China

  • Research Site

    Shanghai, China

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Shatin, Hong Kong

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Rozzano, Italy

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Yokohama, Japan

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.